NF-kB affects migration of vascular smooth muscle cells after treatment with heparin and ibrutinib.

Betulinic acid Collagen Heparin Ibrutinib NF-kB VSMCs

Journal

Biochemistry and biophysics reports
ISSN: 2405-5808
Titre abrégé: Biochem Biophys Rep
Pays: Netherlands
ID NLM: 101660999

Informations de publication

Date de publication:
Jul 2024
Historique:
received: 22 11 2023
revised: 10 02 2024
accepted: 09 03 2024
medline: 25 3 2024
pubmed: 25 3 2024
entrez: 25 3 2024
Statut: epublish

Résumé

The migration of vascular smooth muscle cells (VSMCs) is one of the most important events in the remodeling of atherosclerosis plaque. The aim of study was to investigate the role of Heparin in the VSMC migration and its association with the NF-kB, collagen 1 and collagen 3 expression levels. Moreover, the incorporation of Heparin was studied in the VSMC cultures including Betulinic acid and Ibrutinib. Twelve cell groups were cultured and treated with the Heparin, Betulinic acid and Ibrutinib based on the viability and toxicity in 24-h and 48-h periods. The gene and protein expression levels were measured by RT-qPCR and western blotting techniques. The VSMC migration was determined by scratch test. In contrast with Ibrutinib (2 μM), Heparin (30 IU) increased significantly (P < 0.05) the NF-kB gene and protein expression levels and the VSMC migration during the exposure periods. Heparin (15 IU and 30 IU) also increased the collagen 1 gene expression level in the 48-h period while Heparin (5 IU and 15 IU) increased the collagen 3 gene expression levels in both periods. Incorporating Heparin into the cultures including Betulinic acid and Ibrutinib affected the collagen 1 and collagen 3 expression levels. The data suggested that the cell migration relates to NF-kB in the VSMCs treated with Heparin and Ibrutinib. Furthermore, the Heparin doses (5 IU and 15 IU) were safe for VSMCs based on the NF-kB, and collagen 3 expression levels.

Identifiants

pubmed: 38524279
doi: 10.1016/j.bbrep.2024.101685
pii: S2405-5808(24)00049-9
pmc: PMC10957380
doi:

Types de publication

Journal Article

Langues

eng

Pagination

101685

Informations de copyright

© 2024 The Authors.

Déclaration de conflit d'intérêts

NO.

Auteurs

Nafiseh Shokri (N)

Clinical Biochemistry Department, Faculty of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran.

Ghasem Ghasempour (G)

Clinical Biochemistry Department, Faculty of Medical Sciences, Iran University of Medical Sciences, Tehran, Iran.
Davee Department of Neurology, Feinberg School of Medicine, Northwestern University, Chicago, Illnosis, USA.

Ali Akbar Soleimani (AA)

Clinical Biochemistry Department, Faculty of Medical Sciences, Tehran University of Medical Sciences, Tehran, Iran.

Mohammad Elahimanesh (M)

Clinical Biochemistry Department, Faculty of Medical Sciences, Iran University of Medical Sciences, Tehran, Iran.

Mohammad Najafi (M)

Clinical Biochemistry Department, Faculty of Medical Sciences, Iran University of Medical Sciences, Tehran, Iran.
Microbial Biotechnology Research Center, Iran University of Medical Sciences, Tehran, Iran.

Classifications MeSH